CCLA Investment Management Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

CCLA Investment Management boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 20.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 535,050 shares of the life sciences company’s stock after buying an additional 91,122 shares during the quarter. CCLA Investment Management owned approximately 0.34% of Illumina worth $71,493,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ILMN. Geode Capital Management LLC raised its position in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after acquiring an additional 48,018 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after buying an additional 87,599 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares in the last quarter. Millennium Management LLC grew its position in shares of Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Illumina by 4.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after buying an additional 54,319 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ILMN shares. Royal Bank of Canada lifted their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Canaccord Genuity Group increased their price objective on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Morgan Stanley reduced their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, TD Cowen raised their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Trading Down 5.4 %

Shares of ILMN stock opened at $136.48 on Wednesday. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s fifty day moving average price is $140.55 and its 200 day moving average price is $133.10. The firm has a market capitalization of $21.65 billion, a PE ratio of -13.70 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.33 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.